ES2969960T3 - Método para conjugar un polipéptido - Google Patents
Método para conjugar un polipéptido Download PDFInfo
- Publication number
- ES2969960T3 ES2969960T3 ES15782151T ES15782151T ES2969960T3 ES 2969960 T3 ES2969960 T3 ES 2969960T3 ES 15782151 T ES15782151 T ES 15782151T ES 15782151 T ES15782151 T ES 15782151T ES 2969960 T3 ES2969960 T3 ES 2969960T3
- Authority
- ES
- Spain
- Prior art keywords
- conjugating
- polypeptide
- con
- compound
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000001268 conjugating effect Effects 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000003396 thiol group Chemical group [H]S* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente divulgación se refiere a un método para conjugar un compuesto de fórmula (I) O 5 R1-Q-(ZL-COn-XN O (I) con un polipéptido que comprende al menos un grupo tiol y moléculas obtenidas de dicho método. (Traducción automática con Google Translate, sin valor legal)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462058502P | 2014-10-01 | 2014-10-01 | |
PCT/US2015/053397 WO2016054315A1 (en) | 2014-10-01 | 2015-10-01 | Method of conjugating a polypeptide |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2969960T3 true ES2969960T3 (es) | 2024-05-23 |
Family
ID=54337383
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES15782151T Active ES2969960T3 (es) | 2014-10-01 | 2015-10-01 | Método para conjugar un polipéptido |
Country Status (10)
Country | Link |
---|---|
US (2) | US20170304460A1 (es) |
EP (1) | EP3200829B1 (es) |
JP (1) | JP6863888B2 (es) |
CN (1) | CN106922129B (es) |
AU (1) | AU2015324924B2 (es) |
BR (1) | BR112017006602A2 (es) |
CA (1) | CA2962783A1 (es) |
ES (1) | ES2969960T3 (es) |
RU (1) | RU2715905C2 (es) |
WO (1) | WO2016054315A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA201891482A1 (ru) | 2015-12-21 | 2018-12-28 | Бристол-Маерс Сквибб Компани | Модифицированные антитела для сайт-специфической конъюгации |
GB201602356D0 (en) * | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
KR20230082055A (ko) | 2016-06-17 | 2023-06-08 | 마젠타 테라퓨틱스 인코포레이티드 | 세포의 고갈을 위한 조성물 및 방법 |
WO2018134787A2 (en) | 2017-01-20 | 2018-07-26 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cd137+ cells |
CN108358995B (zh) * | 2017-01-25 | 2021-07-06 | 四川大学 | CP-iRGD多肽、iDPP纳米粒、载药复合物及其制备方法和应用 |
KR20180091773A (ko) | 2017-02-07 | 2018-08-16 | 한미약품 주식회사 | 비펩티드성 중합체 링커 화합물, 그 링커 화합물을 포함하는 결합체, 및 이들의 제조방법 |
HUE056289T2 (hu) | 2017-02-08 | 2022-02-28 | Adc Therapeutics Sa | Pirrolobenzodiazepin-antitest konjugátumok |
CN108864258A (zh) * | 2017-05-12 | 2018-11-23 | 北京康明海慧生物科技有限公司 | 具有抑制肿瘤功能的peg化多肽及其制备方法与应用 |
JP2022531612A (ja) | 2019-05-06 | 2022-07-07 | セーキョー | がん治療のための新規治療用ベクター及びプロドラッグ |
EP4255447A1 (en) * | 2020-12-04 | 2023-10-11 | Dyne Therapeutics, Inc. | Antibody-oligonucleotide complexes and uses thereof |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
DK0744958T3 (da) | 1994-01-31 | 2003-10-20 | Univ Boston | Polyklonale antistofbiblioteker |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
US5830912A (en) | 1996-11-15 | 1998-11-03 | Molecular Probes, Inc. | Derivatives of 6,8-difluoro-7-hydroxycoumarin |
GB9818731D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Compounds |
US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
AU2002218166A1 (en) | 2000-09-08 | 2002-03-22 | Universitat Zurich | Collections of repeat proteins comprising repeat modules |
ATE431851T1 (de) | 2000-12-13 | 2009-06-15 | Anaphore Inc | Methode zur identifikation und isolation von peptide die andere moleküle binden aus kombinatorische proteinbibliotheken mit einer c- typ lectin-ähnlichen domäne als gerüststruktur |
CA2444854A1 (en) | 2001-04-26 | 2002-11-07 | Avidia Research Institute | Combinatorial libraries of monomer domains |
US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
AU2003253048A1 (en) | 2002-07-09 | 2004-01-23 | Morphochem Aktiengellschaft Fur Kombinatorische Chemie | Tubulysin conjugates |
DK2314629T4 (da) | 2002-07-18 | 2023-02-06 | Merus Nv | Rekombinant produktion af blandinger af antistoffer |
WO2005003156A1 (en) | 2003-07-04 | 2005-01-13 | Affibody Ab | Polypeptides having binding affinity for her2 |
US7511032B2 (en) | 2003-10-22 | 2009-03-31 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto |
TW200531979A (en) | 2003-12-05 | 2005-10-01 | Compound Therapeutics Inc | Inhibitors of type 2 vascular endothelial growth factor receptors |
WO2005085251A1 (en) | 2004-03-01 | 2005-09-15 | Spirogen Limited | 11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepines |
GB0410725D0 (en) | 2004-05-13 | 2004-06-16 | Spirogen Ltd | Pyrrolobenzodiazepine therapeutic agents |
DK1879901T3 (da) | 2005-04-21 | 2010-05-03 | Spirogen Ltd | Pyrrolobenzodiazepiner |
CN101370525B (zh) | 2005-08-19 | 2013-09-18 | Abbvie公司 | 双重可变结构域免疫球蛋白及其用途 |
CN101309933A (zh) * | 2005-09-07 | 2008-11-19 | 米迪缪尼有限公司 | 毒素偶联的Eph受体抗体 |
ATE427949T1 (de) | 2005-10-05 | 2009-04-15 | Spirogen Ltd | 4-a4-(5-oxo-2,3,5,11a-tetrahydro-5h-pyrrolo a2, 1-cua1,4ubenzodiazepin-8-yloxy)-butyrylaminou-1 - pyrrol-2-carbonsaurealkylesterderivate und verwandte verbindung zur behandlung einer proliferativen erkrankung |
AU2008282218A1 (en) | 2007-07-31 | 2009-02-05 | Medimmune, Llc | Multispecific epitope binding proteins and uses thereof |
US8633297B2 (en) | 2007-10-31 | 2014-01-21 | Medimmune, Llc | Protein scaffolds |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US20130079280A1 (en) | 2010-04-13 | 2013-03-28 | Medlmmune, Llc | Fibronectin type iii domain-based multimeric scaffolds |
SG187728A1 (en) | 2010-08-06 | 2013-03-28 | Endocyte Inc | Processes for preparing tubulysins |
US20140155581A1 (en) | 2011-07-06 | 2014-06-05 | Medimmune, Llc | Methods For Making Multimeric Polypeptides |
EP2776061B1 (en) | 2011-11-07 | 2019-08-14 | MedImmune, LLC | Multispecific and multivalent binding proteins and uses thereof |
CA2859667C (en) | 2011-12-20 | 2022-05-24 | Medimmune, Llc | Modified polypeptides for bispecific antibody scaffolds |
WO2013121175A1 (en) | 2012-02-16 | 2013-08-22 | Ucl Business Plc | Lysosome-cleavable linker |
SG10201608904YA (en) | 2012-05-15 | 2016-12-29 | Seattle Genetics Inc | Self-Stabilizing Linker Conjugates |
CN104530235A (zh) * | 2012-12-21 | 2015-04-22 | 百奥泰生物科技(广州)有限公司 | 一种抑制肿瘤生长的抗体药物衍生物及其制备方法和用途 |
CN103333246B (zh) * | 2012-12-21 | 2015-09-16 | 百奥泰生物科技(广州)有限公司 | 一种抗egfr受体的肿瘤生长抑制剂及其制备方法和用途 |
-
2015
- 2015-10-01 AU AU2015324924A patent/AU2015324924B2/en not_active Ceased
- 2015-10-01 CN CN201580053082.9A patent/CN106922129B/zh active Active
- 2015-10-01 ES ES15782151T patent/ES2969960T3/es active Active
- 2015-10-01 RU RU2017114343A patent/RU2715905C2/ru active
- 2015-10-01 CA CA2962783A patent/CA2962783A1/en not_active Abandoned
- 2015-10-01 BR BR112017006602A patent/BR112017006602A2/pt not_active IP Right Cessation
- 2015-10-01 JP JP2017517647A patent/JP6863888B2/ja active Active
- 2015-10-01 WO PCT/US2015/053397 patent/WO2016054315A1/en active Application Filing
- 2015-10-01 US US15/516,298 patent/US20170304460A1/en not_active Abandoned
- 2015-10-01 EP EP15782151.3A patent/EP3200829B1/en active Active
-
2021
- 2021-11-16 US US17/527,829 patent/US20220160882A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN106922129A (zh) | 2017-07-04 |
RU2715905C2 (ru) | 2020-03-04 |
EP3200829B1 (en) | 2023-12-06 |
AU2015324924B2 (en) | 2021-07-01 |
US20170304460A1 (en) | 2017-10-26 |
EP3200829A1 (en) | 2017-08-09 |
CN106922129B (zh) | 2024-02-20 |
JP2017535526A (ja) | 2017-11-30 |
AU2015324924A1 (en) | 2017-05-18 |
BR112017006602A2 (pt) | 2017-12-19 |
RU2017114343A (ru) | 2018-11-07 |
CA2962783A1 (en) | 2016-04-07 |
US20220160882A1 (en) | 2022-05-26 |
JP6863888B2 (ja) | 2021-04-21 |
RU2017114343A3 (es) | 2019-04-05 |
WO2016054315A1 (en) | 2016-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2969960T3 (es) | Método para conjugar un polipéptido | |
CL2021000630A1 (es) | Métodos para producir un anticuerpo anti-c5 (divisional de la solicitud no. 201701585) | |
CO2021008696A2 (es) | Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor | |
CO2018006714A2 (es) | 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa | |
EA201891338A1 (ru) | Композиции и способы для иммуноонкологии | |
DOP2018000181A (es) | Terapias de combinación para enfermedades malignas hematológicas con anticuerpos anti-cd38 e inhibidores de survivina | |
CL2016000221A1 (es) | Anticuerpos anti-fgfr2iiib afucosilados. | |
BR112018004620A2 (pt) | moduladores da expressão de kras | |
BR112018006471A2 (pt) | compostos úteis como moduladores de trpm8 | |
EA201890749A1 (ru) | ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) И ИХ ПРИМЕНЕНИЕ | |
EA201891344A1 (ru) | Новые агонисты рецептора апелина и способы применения | |
BR112018005928A2 (pt) | composição ácida compreendendo uma ficocianina | |
CR20180563A (es) | Nuevos derivados piperidinilo sustituidos con hetero(arilo), un proceso para su preparación y composiciones farmacéuticas que lo contienen | |
CO2017005941A2 (es) | Composiciones y métodos para anticuerpos dirigidos a bmp6 | |
BR112018074032A2 (pt) | composições e métodos relacionados a construtos de fc manipulados | |
EA201591961A1 (ru) | Ингибиторы акк и их применение | |
EA201591959A1 (ru) | Ингибиторы акк и их применение | |
EA201591960A1 (ru) | Ингибиторы акк и их применение | |
BR112015032445A2 (pt) | componente semicondutor orgânico | |
BR112017006368A2 (pt) | derivados de ácido borônico | |
BR112015022162A2 (pt) | sonda fluorescente de zinco | |
BR112015019924A2 (pt) | métodos e composições para tratar leucemia | |
CL2017000151A1 (es) | Derivados de piridona | |
BR112017005430A2 (pt) | um polímero orgânico curável que compreende pelo menos uma unidade de acilureia, sua preparação e uso. | |
BR112017013286A2 (pt) | composto de isoxazolina, e, uso de um composto de isoxazolina. |